India to Sri Lanka: Insulin Export Trade Route

The India to Sri Lanka Insulin corridor is one of India's established pharmaceutical export routes, with 36 shipments documented worth a combined $2.5M USD. The route is dominated by M J BIOPHARM PRIVATE LIMITED, which alone accounts for roughly 49% of all export value, reflecting the consolidated nature of India's insulin manufacturing sector.

Across 13 active suppliers, the average shipment value stands at $69.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (68%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during April–June, with an average transit time of 22 days port-to-port. The route has recorded an annual growth rate of 17.3%, placing it at rank #14 among India's top insulin export destinations globally.

On the import side, key buyers of Indian insulin in Sri Lanka include BANK OF CEYLON, BANK OF CEYLON,, EMERCHEMIE NB CEYLON LIMITED and 13 others. BANK OF CEYLON is the single largest importer with 2 shipments valued at $1.2M USD.

India's insulin exports to Sri Lanka are driven primarily by a handful of large-scale manufacturers. M J BIOPHARM PRIVATE LIMITED with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 13 active exporters signals a competitive but concentrated market — buyers in Sri Lanka benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — M J BIOPHARM PRIVATE LIMITED, M. J. BIOPHARM PRIVATE LIMITED, WOCKHARDT LIMITED — together account for 95% of total trade value on this route. The average shipment value of $69.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as biosulin 30:70 biphasic isophane insulin injection ph. eur.100 iu/ml(human insulin rdna origin) (30% as solu and biosulin 30/70 insulin inj.biphasic isophane ph.eur.100 iu/ml,10 ml(human insulin inj.100 iu/ml,10 ml vials)8, suggesting that buyers in Sri Lanka tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BANK OF CEYLON is the largest importer with 2 shipments worth $1.2M USD — representing 49% of all insulin imports from India on this route. A total of 16 buyers are active on this corridor.